Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis-Reference-Cited by-同舟云学术

Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis

Published:2017-01-30 Issue:1 Volume:18 Page:147-158
ISSN:1175-0561
Container-title:American Journal of Clinical Dermatology
language:en
Short-container-title:Am J Clin Dermatol

Author:

Syed Yahiya Y.

Publisher

Springer Science and Business Media LLC

Subject

Dermatology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40257-017-0254-4.pdf

Reference48 articles.

1. International Federation of Psoriasis Associations. Psoriasis is a serious disease deserving global attention. 2016. http://www.ifpa-pso.org . Accessed 20 Dec 2016.

2. World Health Organization. Global report on psoriasis. 2016. http://www.who.int . Accessed 20 Dec 2016.

3. American Academy of Dermatology. Psoriasis. 2016. http://www.aad.org . Accessed 20 Dec 2016.

4. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137–74.

5. Nast A, Gisondi P, Ormerod AD, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris—update 2015—short version—EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277–94.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of brodalumab on psoriasis and depressive symptoms in patients with insufficient response to TNF‐α inhibitors;The Journal of Dermatology;2023-08-31

2. Anti-Drug Antibodies in the Biological Therapy of Autoimmune Rheumatic Diseases;Journal of Clinical Medicine;2023-05-04

3. Drug safety evaluation of ixekizumab for psoriasis: a review of the current knowledge;Expert Opinion on Drug Safety;2022-10-03

4. Multistate modelling of probability of on-treatment clinical response and time remaining in response in patients with moderate-to-severe psoriasis treated with brodalumab or ustekinumab in the AMAGINE-2 and -3 studies;European Journal of Dermatology;2022-07-01

5. Ixekizumab;TURKDERM;2022-05-05